Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders (ExéSemVal)
This protocol describes a study aimed at evaluating the psychometric properties of the ExéSem battery, developed to differentiate semantic deficits from executive semantic impairments in patients with post-lesional or neurodegenerative anomia. Currently available tools do not allow a straightforward distinction between these deficits, limiting diagnostic accuracy and clinical management. The ExéSem battery was developed through a collaboration between Hospices Civils de Lyon, the University of Mons, and Laval University to address this gap.
The battery includes three main tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-picture matching task, and (3) a rapid naming task. Each task is designed to manipulate the level of executive control required to access semantic representations. This allows the identification of whether performance declines under increased executive demand, thereby distinguishing executive-related semantic impairments.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This protocol describes a study aimed at evaluating the psychometric properties of the ExéSem battery, developed to differentiate semantic deficits from executive semantic impairments in patients with post-lesional or neurodegenerative anomia. Currently available tools do not allow a straightforward distinction between these deficits, limiting diagnostic accuracy and clinical management. The ExéSem battery was developed through a collaboration between Hospices Civils de Lyon, the University of Mons, and Laval University to address this gap.
The battery includes three main tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-picture matching task, and (3) a rapid naming task. Each task is designed to manipulate the level of executive control required to access semantic representations. This allows the identification of whether performance declines under increased executive demand, thereby distinguishing executive-related semantic impairments.
The primary objective is to assess the sensitivity of the ExéSem battery by comparing performances between participants with neurocognitive disorders (mild or major) and cognitively healthy controls. Secondary objectives include evaluating specificity, concurrent validity through comparison with established neuropsychological tests (BECLA, Trail Making Test, Stroop), and the influence of demographic variables (age, sex, education level).
This is a prospective, experimental, comparative, single-center study, classified as a non-interventional study involving human participants (RIPH3). Two populations will be included: cognitively healthy individuals and patients diagnosed with Alzheimer's disease, vascular neurocognitive disorder, or semantic variant primary progressive aphasia. Participants will be aged 50 to 90 years, native French speakers, affiliated with a social security system, and informed with non-opposition collected.
The primary endpoint is the total score on the ExéSem battery (maximum score: 172). Secondary endpoints include sub-scores for each task (semantic judgment and matching, word-picture matching, rapid naming), as well as performance on reference tests to assess convergent validity. The effects of age, sex, and education level, as well as task completion times, will also be analyzed.
A single study visit is planned. After receiving information and a reflection period, participants will complete demographic questionnaires and undergo cognitive assessments, including screening tests (MoCA, DTLA for controls), reference tests (Trail Making Test, Stroop, BECLA), and the ExéSem battery. The total duration of testing is approximately 80 minutes, including 30 minutes for ExéSem.
Risks are minimal and mainly related to cognitive fatigue. Participants with abnormal screening results will be referred for further clinical evaluation outside the study. This research aims to improve diagnostic accuracy in semantic disorders and to better guide cognitive rehabilitation strategies.
- Alzheimer's disease
- Vascular neurocognitive disorder
- Progressive Primary Aphasia semantic variant
- People without neurocognitive disorder
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
-
Lyon, Frankrijk, 69100
- Hopital des CHARPENNES ( Hospices Civils de Lyon)
-
Contact:
- Floriane DELPHIN-COMBE, MD
- Telefoonnummer: +33 472433135
- E-mail: Floriane.delphin-combe@chu-lyon.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
The study population includes two groups aged 50 to 90 years: cognitively healthy participants and patients with mild to moderate neurocognitive disorders (MMSE ≥20/30), including Alzheimer's disease, vascular neurocognitive disorder, or semantic variant primary progressive aphasia.
Healthy participants are recruited on a voluntary basis through flyers displayed in the Charpennes Hospital and distributed by speech therapy and neuropsychology students. Interested individuals contact the Clinical Research Center (CRC), where they receive initial information during a phone call and are provided with the study information sheet before scheduling an inclusion visit.
Patients with neurocognitive disorders are recruited during routine clinical care (consultation or day hospital assessment).
Beschrijving
Inclusion Criteria:
- - Participants without cognitive impairment
- Participant aged 50 to 90 years (inclusive);
- Participant whose native language is French
- Participant affiliated with or entitled to a social security scheme;
- Participants who have been informed and have not objected.
- Participants with cognitive impairment
- Participant aged 50 to 90 years (inclusive);
- Participant whose native language is French
- Participant receiving memory care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria (McKahn et al., 2011), or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria (Sachdev et al., 2025), or with a diagnosis of primary progressive aphasia with semantic variant (Gorno-Tempini et al., 2011).
- Mini-Mental State Examination (MMSE) score ≥ 20/30, within the 6 months preceding enrollment;
- Participants affiliated with or entitled to a social security scheme;
- Participants who have been informed and have not objected.
Exclusion Criteria:
- - For all participants:
- Severe, progressive, or unstable medical conditions that may interfere with assessment variables (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection);
- Substance use that may affect cognitive performance;
- Deafness or blindness that may compromise the participant's assessment or participation in tasks and scales;
- Participants under guardianship, curatorship, or legal protection;
- Pregnant, postpartum, or breastfeeding women.
- Specifically for participants without cognitive impairment:
- Participants previously diagnosed with cognitive impairment.
- Specifically for participants with cognitive impairment:
- Severe behavioral and psychological symptoms that prevent task completion, as determined by the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Participants without cognitive impairment
Participanst with a MoCA score greater than or equal to 26/30 and a score greater than the alert threshold based on age and education level on the DTLA scale. Participants who have never received a diagnosis of cognitive impairment. |
The ExéSem battery is a neuropsychological assessment tool designed to evaluate semantic processing and the contribution of executive control in patients with or without neurocognitive disorders.
It consists of three tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-to-picture matching task, and (3) a rapid naming task.
Each task is structured to manipulate the level of executive demand required to access semantic representations.
This variation allows the identification of whether semantic difficulties remain stable or worsen under increased executive load, thereby distinguishing primary semantic deficits from executive-related semantic impairments.
The battery is administered by a trained professional using standardized instructions and requires approximately 30 minutes to complete.
It is used for diagnostic and research purposes only and does not involve any therapeutic intervention.
|
|
Participants with Cognitive Impairment
Participants receiving memory clinic care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria, or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria , or with a diagnosis of primary progressive aphasia with semantic variant.
Participants with a Mini-Mental State Examination (MMSE) score ≥ 20/30, within the 6 months preceding enrollment;
|
The ExéSem battery is a neuropsychological assessment tool designed to evaluate semantic processing and the contribution of executive control in patients with or without neurocognitive disorders.
It consists of three tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-to-picture matching task, and (3) a rapid naming task.
Each task is structured to manipulate the level of executive demand required to access semantic representations.
This variation allows the identification of whether semantic difficulties remain stable or worsen under increased executive load, thereby distinguishing primary semantic deficits from executive-related semantic impairments.
The battery is administered by a trained professional using standardized instructions and requires approximately 30 minutes to complete.
It is used for diagnostic and research purposes only and does not involve any therapeutic intervention.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Score obtained on the ExéSem battery
Tijdsspanne: At enrollment
|
The primary outcome is the total score on the ExéSem battery (max=172), assessing semantic and executive-semantic processing.
The battery includes semantic judgment (30 items), semantic matching (20 items), word-image matching (72 items), and rapid naming (50 items).
Tasks vary in executive demand to determine whether performance declines under increased cognitive load, distinguishing primary semantic deficits from executive-related impairments.
|
At enrollment
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neurologische gedragsmanifestaties
- Dementie
- Tauopathieën
- Neurodegeneratieve ziekten
- Communicatiestoornissen
- Taalstoornissen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Ziekte van Alzheimer
- Neurocognitieve stoornissen
- Anomie
Andere studie-ID-nummers
- 69HCL25_1144
- 2025-A02845-44 (Andere identificatie: ID-RCB)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .